Matisse Pharmaceuticals
PrivateLast Round
Series A
Sep 17, 2026
Total Funding Raised
$16.68M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Matisse Pharmaceuticals is a biopharmaceutical company developing therapies for the treatment of sepsis and other inflammatory conditions characterized by elevated levels of circulating cytotoxic histones.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Matisse Pharmaceuticals Comparables
Compare Matisse Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Inotrem | 86% | |
| Adrenomed AG | 83% | |
| RevImmune | 81% | |
Matisse Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 17, 2026 | ||||
| Grant | Jun 26, 2025 | ||||
| VC Round | Jan 4, 2024 | ||||
| VC Round | Mar 1, 2020 | ||||
| Seed | Nov 15, 2016 |
Matisse Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mibiton Foundation | Seed |
| Eurostars SME programme | Grant |
| Brightlands Venture Partners | Series A, VC Round, Seed |
| LIOF | Series A, VC Round, Seed |
| Particon B.V. | Seed |
| Netherlands Enterprise Agency | VC Round, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 17, 2026
$16M round led by Brightlands Venture Partners and LIOF.
- Jul 28, 2026
Monthly visitors grew 205% MoM.
Matisse Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Matisse Pharmaceuticals's valuation, stock price, and market status.